Uma Giri Selected Research

Adenocarcinoma of Lung

8/2015

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Uma Giri Research Topics

Disease

18	Neoplasms (Cancer) 01/2022 - 03/2006
14	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 08/2011
6	Squamous Cell Carcinoma of Head and Neck 01/2019 - 05/2009
6	Lung Neoplasms (Lung Cancer) 01/2018 - 01/2013
3	Neoplasm Metastasis (Metastasis) 01/2021 - 12/2013
3	Head and Neck Neoplasms (Head and Neck Cancer) 01/2019 - 04/2011
2	Carcinogenesis 01/2019 - 12/2013
2	Lymphoma (Lymphomas) 01/2011 - 11/2009
1	Colonic Neoplasms (Colon Cancer) 01/2019
1	Vascular Remodeling 09/2017
1	Circulating Neoplastic Cells 03/2016
1	Adenocarcinoma of Lung 08/2015
1	Breast Neoplasms (Breast Cancer) 01/2015
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2015
1	Hematologic Neoplasms (Hematological Malignancy) 01/2015
1	Hypoxia (Hypoxemia) 08/2011
1	Pancreatic Neoplasms (Pancreatic Cancer) 11/2009
1	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 05/2009

Drug/Important Bio-Agent (IBA)

6	Biomarkers (Surrogate Marker)IBA 09/2017 - 04/2011
3	MicroRNAs (MicroRNA)IBA 01/2019 - 05/2009
3	Messenger RNA (mRNA)IBA 01/2019 - 05/2009
3	Proteins (Proteins, Gene)FDA Link 12/2015 - 04/2011
2	Adenosine Triphosphate (ATP)IBA 01/2022 - 01/2015
2	Tyrosine Kinase InhibitorsIBA 07/2016 - 03/2016
2	Polo-Like Kinase 1IBA 07/2016 - 04/2016
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2016 - 08/2011
2	PlatinumIBA 04/2016 - 08/2011
2	Pharmaceutical PreparationsIBA 07/2014 - 01/2013
2	Glutathione (Reduced Glutathione)IBA 01/2011 - 11/2009
1	NucleosidesIBA 01/2022
1	NADP (NADPH)IBA 01/2022
1	NucleotidesIBA 01/2022
1	GlutaminaseIBA 01/2021
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 09/2017
1	ErbB Receptors (EGF Receptor)IBA 07/2016
1	DNA (Deoxyribonucleic Acid)IBA 04/2016
1	vandetanib (ZD6474)IBA 04/2016
1	Docetaxel (Taxotere)FDA Link 04/2016
1	Circulating Tumor DNAIBA 03/2016
1	Dasatinib (BMS 354825)FDA Link 01/2016
1	Phosphotransferases (Kinase)IBA 01/2016
1	Mechanistic Target of Rapamycin Complex 1IBA 08/2015
1	Transcription Factors (Transcription Factor)IBA 08/2015
1	8-chloroadenosineIBA 01/2015
1	Adenosine (Adenocard)FDA LinkGeneric 01/2015
1	Biological ProductsIBA 12/2014
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 12/2014
1	Sorafenib (BAY 43-9006)FDA Link 12/2014
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 07/2014
1	Radiation-Sensitizing AgentsIBA 07/2014
1	Lysine (L-Lysine)FDA Link 12/2013
1	Histones (Histone)IBA 12/2013
1	Metformin (Glucophage)FDA LinkGeneric 01/2012
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 08/2011
1	AntibodiesIBA 04/2011
1	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 04/2011
1	Reactive Oxygen Species (Oxygen Radicals)IBA 11/2009
1	aziridine (ethyleneimine)IBA 11/2009
1	4- imino- 1,3- diazabicyclo(3.1.0)hexan- 2- oneIBA 11/2009
1	Apoptosis Regulatory ProteinsIBA 05/2009
1	Transforming Growth Factor beta Receptors (TGF beta Receptors)IBA 05/2009
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 05/2009

Therapy/Procedure

9	Radiotherapy 01/2021 - 03/2006
6	Therapeutics 01/2021 - 08/2011
3	Drug Therapy (Chemotherapy) 01/2021 - 08/2011
1	Aftercare (After-Treatment) 09/2016
1	Adjuvant Chemotherapy 08/2011